To demonstrate a long-term survival benefit without a new trial, Neuvivo hired a research firm to track down patients from the original study. By collecting "last date alive" information in a blinded fashion, they generated statistically significant survival data years after the trial concluded.

Despite the drug having a 90-minute half-life, patients maintained and even saw continued improvement eight months after stopping the 12-week treatment. This suggests the drug facilitates genuine neural repair and rewiring, rather than offering only temporary symptomatic relief that requires continuous dosing.

Stoke's therapy for Dravet syndrome employs a unique "upregulation" mechanism. Instead of knocking out a faulty gene or delivering a new one, its ASO targets the existing healthy gene to produce more of the needed NAV1.1 protein. This approach is specifically designed for haploinsufficient diseases where one gene copy is functional but insufficient.

For a slow-progressing illness like Huntington's, a placebo effect can mask any real drug benefit in a short trial. The strength of the uniQure study is its three-year duration, long enough for the disease's progression to outpace any temporary placebo effect—a nuance the FDA's one-year assessment misses.

Stoke emphasizes that reducing seizures is only part of its goal. The true measure of success for its Dravet syndrome therapy is restoring cognitive and behavioral function, as demonstrated by the Vineland-3 scale. This focus on neurotypical development and quality of life represents a more holistic approach to treating the disease.

Beyond nearly doubling survival rates, Immuneering emphasizes concrete quality of life improvements, such as a patient regaining the ability to drive. This patient-centric narrative powerfully demonstrates the drug's real-world impact and differentiates it from therapies with grueling side effects.

The company is well-capitalized with a cash runway extending into 2028, beyond the potential 2027 approval of its Dravet syndrome drug. This strong financial position is bolstered by a strategic co-funding collaboration with Biogen, providing significant stability and de-risking the company's path to commercialization.

Contrary to the belief that recovery is limited to the months post-injury, NervGen's trial specifically enrolled and showed significant functional improvement in patients with chronic injuries, some a decade old. This opens a new treatment window for a large, previously overlooked patient population.

The company's clinical trials go beyond standard pain scores to track improvements in function, sleep, and patient satisfaction. Demonstrating that patients can climb stairs, drive, and sleep better provides a more compelling value proposition for a faster return to normal life, resonating with patients, surgeons, and payers alike.